Corporate Overview
Shuttle Pharmaceuticals (Nasdaq: SHPH) is a clinical-stage pharmaceutical company leveraging our proprietary technology to develop novel therapies that are designed to cure cancer. Our goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. Radiation therapy (RT) is among the most effective and proven treatment modalities for curing cancers.
The Company has developed technologies to sensitize growing cancer cells, rendering them susceptible to the effects of radiation therapy, and activate the DNA damage response pathway to kill cancer cells and protect adjacent normal cells. In addition, the Company’s in-licensed diagnostic tests and theranostic molecules offer to enhance staging and treatment of prostate cancers.
Videos & Presentations
Recent News
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
Recent Events
Investor Contacts
Company
Shuttle Pharmaceuticals
401 Professional Drive, Suite 260
Gaithersburg, MD 20879
Phone: 240-430-4212
Email: info@shuttlepharma.com
Investor Relations
Lytham Partners, LLC
Robert Blum
Phone: 602-889-9700
Email: shph@lythampartners.com
Transfer Agent
Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179
Email: info@vstocktransfer.com
Website: www.VStockTransfer.com